Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis

P. L. Bailin, J. P. Tindall, H. H. Roenigk Jr and M. D. Hogan

The use of methotrexate in psoriasis has recently been questioned because of possible carcinogenic potential. Two hundred twenty-four patients began methotrexate therapy during 1960 to 1965 at the Cleveland Clinic and at Duke University Medical Center. The incidence of malignant neoplasms and mortality has been studied in 205 of these 224 patients. Mortality increased with hepatic disease. No increased incidence of total internal malignancy was found, nor did any one type of neoplasm appear predominant.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
Farrell et al.
Gut 2000;47:514-519.
ABSTRACT | FULL TEXT  

Statement on Sarcoidosis
Hunninghake
Am. J. Respir. Crit. Care Med. 1999;160:736-755.
FULL TEXT  

A clinical approach to the use of methotrexate for sarcoidosis
Baughman and Lower
Thorax 1999;54:742-746.
FULL TEXT  

Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate
Bologna et al.
Ann Rheum Dis 1997;56:97-102.
ABSTRACT | FULL TEXT  

Second-Line Drug Therapy for Rheumatoid Arthritis
Cash and Klippel
NEJM 1994;330:1368-1375.
FULL TEXT  

Reversible Lymphomas Associated with Epstein-Barr Virus Occurring during Methotrexate Therapy for Rheumatoid Arthritis and Dermatomyositis
Kamel et al.
NEJM 1993;328:1317-1321.
FULL TEXT